Primary maxillary sinus lymphoma
Authors:
Open Access
- 24 November 2017
- journal article
- editorial
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 111 (2) , 119-120
Abstract
Primary paranasal sinus non-Hodgkin lymphoma (NHL) is rarely encountered in clinical practice, composing less than 0.5–1.5% of B-cell lymphoma.1 Given its pauciKeywords
Funding Information
- National Natural Science Foundation of China (81602659)
This publication has 5 references indexed in Scilit:
- Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of LymphomaLeukemia & Lymphoma, 2014
- CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom?Blood Reviews, 2012
- Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)Annals of Oncology, 2006
- Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxisLeukemia & Lymphoma, 2005
- Primary diffuse large B‐cell non‐Hodgkin lymphoma of the paranasal sinuses: a report of 14 casesBritish Journal of Haematology, 2005